Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

784 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A.
Pavlova A, Delev D, Lacroix-Desmazes S, Schwaab R, Mende M, Fimmers R, Astermark J, Oldenburg J. Pavlova A, et al. Among authors: oldenburg j. J Thromb Haemost. 2009 Dec;7(12):2006-2015. doi: 10.1111/j.1538-7836.2009.03636.x. J Thromb Haemost. 2009. PMID: 19817985 Free article.
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.
Schwarz J, Astermark J, Menius ED, Carrington M, Donfield SM, Gomperts ED, Nelson GW, Oldenburg J, Pavlova A, Shapiro AD, Winkler CA, Berntorp E; Hemophilia Inhibitor Genetics Study Combined Cohort. Schwarz J, et al. Among authors: oldenburg j. Haemophilia. 2013 Jan;19(1):113-8. doi: 10.1111/hae.12004. Epub 2012 Sep 7. Haemophilia. 2013. PMID: 22958194 Free PMC article.
Haemophilia Inhibitor Genetics Study - evaluation of a model for studies of complex diseases using linkage and association methods.
Berntorp E, Astermark J, Donfield SM, Nelson GW, Oldenburg J, Shapiro AD, Dimichele DM, Ewenstein BM, Gomperts ED, Winkler CA; Hemophilia Inhibitor Genetics Study. Berntorp E, et al. Among authors: oldenburg j. Haemophilia. 2005 Jul;11(4):427-9. doi: 10.1111/j.1365-2516.2005.01119.x. Haemophilia. 2005. PMID: 16011603 No abstract available.
Malignant disease in the haemophilic population: moving towards a management consensus?
Astermark J, Makris M, Mauser-Bunschoten E, Nemes L, D'oiron R, Oldenburg J, Ingerslev J; Malignancy in Haemophilia Workshop Group. Astermark J, et al. Among authors: oldenburg j. Haemophilia. 2012 Sep;18(5):664-71. doi: 10.1111/j.1365-2516.2012.02846.x. Epub 2012 May 28. Haemophilia. 2012. PMID: 22630161 Review.
European retrospective study of real-life haemophilia treatment.
Berntorp E, Dolan G, Hay C, Linari S, Santagostino E, Tosetto A, Castaman G, Álvarez-Román MT, Parra Lopez R, Oldenburg J, Albert T, Scholz U, Holmström M, Schved JF, Trossaërt M, Hermans C, Boban A, Ludlam C, Lethagen S. Berntorp E, et al. Among authors: oldenburg j. Haemophilia. 2017 Jan;23(1):105-114. doi: 10.1111/hae.13111. Epub 2016 Oct 20. Haemophilia. 2017. PMID: 27761962
Factor VIII intron-1 inversion: frequency and inhibitor prevalence.
Schröder J, El-Maarri O, Schwaab R, Müller CR, Oldenburg J. Schröder J, et al. Among authors: oldenburg j. J Thromb Haemost. 2006 May;4(5):1141-3. doi: 10.1111/j.1538-7836.2006.01884.x. J Thromb Haemost. 2006. PMID: 16689771 Free article. No abstract available.
784 results